Moxifloxacin Hydrochloride (Anhydrous) API

Mechanism of Action

The bactericidal action of moxifloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV. DNA gyrase is an essential enzyme that is involved in the replication, transcription and repair of bacterial DNA. Topoisomerase IV is an enzyme known to play a key role in the partitioning of the chromosomal DNA during bacterial cell division.

Indication

AVELOX is a fluoroquinolone antibacterial indicated for treating infections in adults 18 years of age and older caused by designated susceptible bacteria, in the conditions listed below: 

• Community Acquired Pneumonia
• Skin and Skin Structure Infections: Uncomplicated and Complicated
• Complicated Intra-Abdominal Infections
• Plague
• Acute Bacterial Sinusitis
• Acute Bacterial Exacerbation of Chronic Bronchitis 

To reduce the development of drug-resistant bacteria and maintain the effectiveness of AVELOX and other antibacterial drugs. AVELOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria VIGAMOX® solution is a topical fluoroquinolone antiinfective indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: 

• Corynebacterium species*
• Micrococcus luteus*
• Staphylococcus aureus
• Staphylococcus epidermidis
• Staphylococcus haemolyticus
• Staphylococcus hominis
• Staphylococcus warneri*
• Streptococcus pneumoniae
• Streptococcus viridans group
• Acinetobacter lwoffii*
• Haemophilus influenzae
• Haemophilus parainfluenzae*
• Chlamydia trachomatis

Dr. Reddy's Expertise

Headquartered in Hyderabad, India, Dr. Reddy's Laboratories is one of the leading Active Pharmaceutical Ingredients (API) manufacturers and suppliers globally for Moxifloxacin Hydrochloride (Anhydrous) API. Dr. Reddy's API business is a preferred partner to pharma companies across the US, Europe, Brazil, Latin America, Japan, China, Korea, Middle East and other emerging markets.

Dr. Reddy's API business thrives on the deep technical strengths established over the last 30+ years in the development and manufacture of complex APIs such as steroids, peptides, complex long chain molecules and highly potent APIs (HPAPIs / oncology drugs). This expertise is complemented by our prowess in intellectual property and regulatory affairs which helps us consistently meet and exceed regulatory standards. Dr. Reddy's Moxifloxacin Hydrochloride (Anhydrous) API is the outcome of the extensive expertise in R&D, IP, and Regulatory.

A key component in helping our customers be first to market is a responsive supply chain. We achieve this by making sure that all our facilities are operating efficiently and to the latest standards of quality, safety, and productivity. A strong interconnect between business and factories allows for a quick reaction to dynamic market changes, so that we can avert shortages and meet sudden surges in demand.